Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
LY3819253
DRUG
5 trials
Sponsors
Eli Lilly and Company
, National Institute of Allergy and Infectious Diseases (NIAID)
Conditions
COVID-19
Covid19
Healthy
Phase 1
A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19
Completed
NCT04411628
Eli Lilly and Company
COVID-19
Start: 2020-05-28
End: 2020-08-26
Updated: 2021-11-12
A Study of LY3819253 (LY-CoV555) in Healthy Participants
Completed
NCT04537910
Eli Lilly and Company
Healthy
Start: 2020-09-02
End: 2020-12-28
Updated: 2021-12-06
Phase 2
A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness
Completed
NCT04427501
Eli Lilly and Company
COVID-19
Start: 2020-06-17
End: 2023-02-21
Updated: 2024-04-11
Phase 3
ACTIV-3: Therapeutics for Inpatients With COVID-19
Completed
NCT04501978
National Institute of Allergy and Infectious Diseases (NIAID)
Covid19
Start: 2020-08-04
End: 2023-07-14
Updated: 2023-08-25
LY3819253 (LY-CoV555) for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
Completed
NCT05780268
National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
Start: 2020-08-05
End: 2021-02-01
Updated: 2023-12-27
Related Papers
The Safety and Pharmacokinetics of the Neutralizing Monoclonal Antibody Bebtelovimab in Pediatric Patients with Mild-to-Moderate COVID-19 to Inform Pandemic Preparedness
Open Forum Infectious Diseases
2025-11-20
Long-term outcomes of passive immunotherapy for COVID-19: a pooled analysis of a large multinational platform randomized clinical trial
Clinical Microbiology and Infection
2025-02-06
2 citations
P-1904. The Interaction of Serum Biomarkers and Lymphopenia on Pulmonary COVID-19 Illness Progression in Hospitalized Patients
Open Forum Infectious Diseases
2025-01-29
Efficacy and Safety of Low-Dose, Rapidly Infused Bamlanivimab and Etesevimab: Phase 3 BLAZE-1 Trial for Mild-to-Moderate COVID-19.
2024-09-04
1 citations
Effect of Neutralizing Monoclonal Antibody Treatment on Early Trajectories of Virologic and Immunologic Biomarkers in Patients Hospitalized With COVID-19
The Journal of Infectious Diseases
2023-11-09
4 citations
Pharmacokinetics, Efficacy, and Safety of a SARS-CoV-2 Antibody Treatment in Pediatric Participants: An Open-Label Addendum of a Placebo-Controlled, Randomized Phase 2/3 Trial
Infectious Diseases and Therapy
2023-06-17
1 citations
Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19 : A Randomized Controlled Trial.
2022-08-09
22 citations
Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial.
2022-07-08
96 citations
Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial.
2022-06-07
173 citations
Bamlanivimab and Etesevimab Improve Symptoms and Associated Outcomes in Ambulatory Patients at Increased Risk for Severe Coronavirus Disease 2019: Results From the Placebo-Controlled Double-Blind Phase 3 BLAZE-1 Trial
Open Forum Infectious Diseases
2022-04-07
10 citations
Relationship between gene expression patterns from nasopharyngeal swabs and serum biomarkers in patients hospitalized with COVID-19, following treatment with the neutralizing monoclonal antibody bamlanivimab.
2022-03-18
11 citations
RAGE has potential pathogenetic and prognostic value in nonintubated hospitalized patients with COVID-19
JCI Insight
2022-03-17
27 citations
The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans
Science Translational Medicine
2022-01-25
208 citations
Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial.
2021-12-23
173 citations
Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels : A Randomized Controlled Trial.
2021-12-21
69 citations
A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load
Clinical Infectious Diseases
2021-10-27
68 citations
A Quantitative Modeling and Simulation Framework to Support Candidate and Dose Selection of Anti‐SARS‐CoV‐2 Monoclonal Antibodies to Advance Bamlanivimab Into a First‐in‐Human Clinical Trial
Clinical Pharmacology & Therapeutics
2021-10-23
23 citations
First‐in‐Human Study of Bamlanivimab in a Randomized Trial of Hospitalized Patients With COVID‐19
Clinical Pharmacology & Therapeutics
2021-08-29
31 citations
A Narrative Review of the Clinical Practicalities of Bamlanivimab and Etesevimab Antibody Therapies for SARS-CoV-2.
2021-08-10
29 citations
Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19
New England Journal of Medicine
2021-07-14
654 citations
4 more papers not shown